Lung Cancer, Nonsmall Cell
Conditions
Brief summary
The purpose of this study is to examine the association between ctDNA/immune biomarkers and disease progression in patients who, at immunotherapy discontinuation, have completed at least 20 of an anticipated 24 months of immune checkpoint inhibitor monotherapy or immune checkpoint inhibitor combination chemotherapy for mNSCLC.
Detailed description
This is a prospective, non-randomized, pilot study. The target population is adults ≥18 years of age with metastatic non-small cell lung cancer that at immunotherapy discontinuation, have completed at least 20 of an anticipated 24 months of planned doses of immune checkpoint inhibitor treatment in the first line setting. The study will be conducted at various Atrium Health Wake Forest Baptist Comprehensive Cancer Center locations. Subjects will have blood for ctDNA and immune markers collected at baseline, and every 3 months for up to approximately 6 months. Blood will be collected at disease progression if it occurs prior to 6 months, ensuring that the collection occurs prior to start of subsequent anti-cancer therapy. We will also collect data from standard of care CT scans every 3 months for up to 6 months or until disease progression. In patients undergoing standard of care biopsies, a portion of tumor tissue will be obtained and tested for tumor mutations. Archived tumor tissue collected pre-immunotherapy (if available) will also be tested.
Interventions
Blood and tissue will be collected to perform ctDNA and immune biomarkers assessment to predict progression within 6 months of immune checkpoint inhibitor treatment discontinuation.
Sponsors
Wake Forest University Health Sciences
Atrium Health Levine Cancer Institute
Atrium Health Wake Forest Baptist
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Informed consent and HIPAA authorization for release of personal health information signed by the subject. Note: Data from tumor samples, blood samples and radiographic scans prior to enrollment date may be used. 2. Age greater than or equal to18 years at the time of consent. 3. Patients with metastatic non-small cell lung carcinoma have completed first line who, at immunotherapy discontinuation, have completed at least 20 of an anticipated 24 months of immune checkpoint inhibitor monotherapy or pembrolizumab combination chemotherapy in the first line setting. 4. Patients are allowed to continue maintenance chemotherapy. 5. Ability to understand and comply with study procedures for the entire length of the study. 6. Known PD-L1 prior to initiation of first-line treatment for NSCLC.
Exclusion criteria
1. Enrollment/collection of baseline sample earlier than 7 days prior to scheduled last dose of immune checkpoint inhibitor treatment or more than 30 days after last dose of immune checkpoint inhibitor treatment. 2. Patients whose tumors harbor known first line treatment druggable gene abnormalities (e.g. EGFR, BRAF, ALK, ROS1). 3. Patients who have ever received or are currently receiving other types of immunotherapies (nivolumab, ipilimumab, durvalumab or atezolizumab). 4. Known pregnancy. 5. Patients who progress per the enrolling investigator while on treatment with immune checkpoint inhibitor treatment prior to enrollment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Disease progression status for the purpose of assessing its correlation with ctDNA measured at 0 months after pembrolizumab treatment completion | 6 months after immune checkpoint inhibitor treatment completion | Disease progression status determined by the treating investigator per standard care |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Disease progression status for the purpose of assessing its correlation with circulating effector T cell anergy at 0 months after pembrolizumab treatment completion | 6 months after immune checkpoint inhibitor treatment completion | Disease progression status determined by the treating investigator per standard care |
| Disease progression status for the purpose of assessing its correlation with the rate of effector to central memory T cell conversion at 0 months after pembrolizumab treatment completion | 6 months after immune checkpoint inhibitor treatment completion | Disease progression status determined by the treating investigator per standard care |
| Disease progression status for the purpose of assessing its correlation with clonal circulating T cell diversity at 0 months after pembrolizumab treatment completion | 6 months after immune checkpoint inhibitor treatment completion | Disease progression status determined by the treating investigator per standard care |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORKathryn Mileham, MD
Atrium Health Levine Cancer
Outcome results
None listed